文献速递乳腺癌

卡维地洛阻断乳腺癌神经调控并与降低乳腺癌死亡率相关

Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
PubMed 文献 · Eur J Cancer · 2021-02-24

该研究探讨β受体阻滞剂卡维地洛对乳腺癌的影响,在细胞系、小鼠模型及4014例乳腺癌患者队列中进行分析。结果显示卡维地洛可阻断交感神经系统激活、减少小鼠原发肿瘤生长和转移,并在一项回顾性分析中与乳腺癌特异性死亡率降低相关。

要点

  • 卡维地洛在乳腺癌小鼠模型中减少原发肿瘤生长和转移。
  • 诊断时使用卡维地洛与乳腺癌特异性死亡率降低相关(5年累积发生率3.1% vs 5.7%)。
  • 结果为探索卡维地洛作为抗癌策略提供依据。

核心结论

  • 卡维地洛可阻断交感神经系统对乳腺癌进展的驱动作用,并与乳腺癌患者死亡率降低相关。

研究设计与样本

  • 研究包括乳腺癌细胞系实验、乳腺癌小鼠模型以及4014例乳腺癌患者的大型队列回顾性分析。

主要发现

  • 卡维地洛治疗阻断了交感神经系统激活的效应,减少小鼠模型原发肿瘤生长和转移,并防止乳腺癌细胞系侵袭。
  • 诊断时使用卡维地洛的136例女性与未使用的3878例女性相比,乳腺癌特异性死亡率降低,5年累积发生率分别为3.1%和5.7%(p=0.024和0.076,分别来自单变量和多变量分析),中位随访5.5年。

临床怎么用

  • 这些发现为进一步探索β受体阻滞剂卡维地洛作为减缓癌症进展的新策略提供了依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The sympathetic nervous system drives breast cancer progression through β-adrenergic receptor signalling. This discovery has led to the consideration of cardiac β-blocker drugs as novel strategies for anticancer therapies. Carvedilol is a β-blocker used in the management of cardiovascular disorders, anxiety, migraine and chemotherapy-induced cardiotoxicity. However, little is known about how carvedilol affects cancer-related outcomes. METHODS: To address this, we investigated the effects of carvedilol on breast cancer cell lines, in mouse models of breast cancer and in a large cohort of patients with breast cancer (n = 4014). RESULTS: Treatment with carvedilol blocked the effects of sympathetic nervous system activation, reducing primary tumour growth and metastasis in a mouse model of breast cancer and preventing invasion by breast cancer cell lines. A retrospective analysis found that women using carvedilol at breast cancer diagnosis (n = 136) had reduced breast cancer-specific mortality compared with women who did not (n = 3878) (5-year cumulative incidence of breast cancer deaths: 3.1% versus 5.7%; p = 0.024 and 0.076 from univariate and multivariable analyses, respectively) after a median follow-up of 5.5 years. CONCLUSIONS: These findings provide a rationale to further explore the use of the β-blocker carvedilol as a novel strategy to slow cancer progression.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gillis RD, Botteri E, Chang A, et al. Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. Eur J Cancer. 2021. PMID: 33639323. doi:10.1016/j.ejca.2021.01.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。